-
Neuropsychiatric Disease and Treatment
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Update on the use of memantine in Alzheimer’s disease
Review
(3929) Views (894) Full article downloads
Authors: Robert J van Marum
Published Date March 2009
Volume 2009:5 Pages 237 - 247
DOI: http://dx.doi.org/10.2147/NDT.S4048
Robert J van Marum
Geriatric Department, University Medical Center Utrecht, Utrecht, The Netherlands
Abstract: Memantine is a low to moderate affinity N-methyl-D-aspartate receptor (NMDAR) antagonist. The effects of memantine in Alzheimer’s disease (AD) have been studied in 7 randomized controlled trials in many post-hoc analyses. Three out of four RCTs in patients with moderate to severe AD (Mini Mental State Examination [MMSE] 14) showed a statistically significant but clinically small positive effect of memantine on cognition, global functioning, activities of daily living (ADL) and neuropsychiatric symptoms. No effects on these outcome measures could be found in the three RCTs studying patients with mild to moderate AD (MMSE 14–24). Two of these studies evaluated the effect of addition of memantine to donepezil. Only the study in patients with mild to moderate AD showed a positive effect of addition of memantine on cognition, ADL, global functioning and neuropsychiatric functioning. Cost-effectiveness of memantine therapy remains controversial. Post-hoc analyses and observational studies suggest some effects on agitation/aggression, delusions or hallucinations. Side effects of memantine are usually mild and seem to be comparable with placebo. In this review, an oversight of pharmacodynamics and pharmacokinetics of memantine is presented. Also, published data concerning efficacy and safety in patients with AD are presented.
Keywords: dementia, Alzheimer’s disease, drug therapy, memantine
Readers of this article also read:
A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Sleep disorders in Parkinson’s disease
The pathophysiology of bronchiectasis
Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
Health literacy and health seeking behavior among older men in a middle-income nation
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
- Implementing the 2009 Institute of Medicine recommendations on resident physician work hours, supervision, and safety
- Moderate alcohol consumption and cognitive risk
- Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference




